Acquisition by Suneel Gupta of 85000 shares of Protagonist Therapeutics at 7.8 subject to Rule 16b-3
PTGX Stock | USD 40.69 0.77 1.86% |
Slightly above 55% of Protagonist Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Protagonist Therapeutics suggests that many traders are impartial. Protagonist Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Protagonist Therapeutics' earnings reports, geopolitical events, and overall market trends.
Protagonist |
Filed transaction by Protagonist Therapeutics Officer: Chief Development Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at news.google.com
Protagonist Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Protagonist Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Protagonist Therapeutics Fundamental Analysis
We analyze Protagonist Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagonist Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagonist Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
Protagonist Therapeutics is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Protagonist Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Protagonist Therapeutics stock to make a market-neutral strategy. Peer analysis of Protagonist Therapeutics could also be used in its relative valuation, which is a method of valuing Protagonist Therapeutics by comparing valuation metrics with similar companies.
Peers
Protagonist Therapeutics Related Equities
XFOR | X4 Pharmaceuticals | 13.85 | ||||
KURA | Kura Oncology | 3.63 | ||||
PLRX | Pliant Therapeutics | 2.78 | ||||
IDYA | Ideaya Biosciences | 2.35 | ||||
VTYX | Ventyx Biosciences | 2.11 | ||||
ARVN | Arvinas | 0.58 | ||||
RVMD | Revolution Medicines | 0.16 | ||||
SNDX | Syndax Pharmaceuticals | 0.15 | ||||
VRNA | Verona Pharma | 0.1 | ||||
RNA | Avidity Biosciences | 0.24 | ||||
DAWN | Day One | 0.71 | ||||
RLAY | Relay Therapeutics | 0.89 | ||||
HOOK | Hookipa Pharma | 1.84 | ||||
STOK | Stoke Therapeutics | 2.31 | ||||
MRUS | Merus BV | 2.38 | ||||
ABOS | Acumen Pharmaceuticals | 2.96 | ||||
AKRO | Akero Therapeutics | 3.10 | ||||
BDTX | Black Diamond | 5.30 | ||||
REPL | Replimune | 5.93 | ||||
TERN | Terns Pharmaceuticals | 8.82 |
Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.